A Closer Look at CSL (ASX:CSL) Valuation Following Capital Markets Day and Guidance Downgrade

Simply Wall St.

Nov 05

CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581832704"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581832704\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581832704?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2025-11-05 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581832704","market":"hk","top_or_hot":-1,"title":"A Closer Look at CSL (ASX:CSL) Valuation Following Capital Markets Day and Guidance Downgrade","media":"Simply Wall St.","content":"<div>\n<p>CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-closer-look-at-csl-asxcsl-valuation-following-capital-mark\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Closer Look at CSL (ASX:CSL) Valuation Following Capital Markets Day and Guidance Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Closer Look at CSL (ASX:CSL) Valuation Following Capital Markets Day and Guidance Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-05 21:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-closer-look-at-csl-asxcsl-valuation-following-capital-mark><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-closer-look-at-csl-asxcsl-valuation-following-capital-mark\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-closer-look-at-csl-asxcsl-valuation-following-capital-mark","article_id":"2581832704","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-closer-look-at-csl-asxcsl-valuation-following-capital-mark","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581832704","pubTimestamp":1762349753,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade and market volatility.\nSee our latest analysis for CSL.\nDespite promising long-term trends in core plasma and vaccine markets, CSL’s share price return has slid sharply this year, with a 30-day drop of 14.3% and a year-to-date fall of 37.3%. After briefly rallying on hopes for operational...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"资本市场日和指引下调后仔细审视CSL(ASX：CSL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5},"content_text":"CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade and market volatility. See our latest analysis for CSL. Despite promising long-term trends in core plasma and vaccine markets, CSL’s share price return has slid sharply this year, with a 30-day drop of 14.3% and a year-to-date fall of 37.3%. After briefly rallying on hopes for operational improvements, the momentum has faded following October’s revenue guidance downgrade and board changes. This has led to a one-year total shareholder return of -37%. Investors are now closely watching management’s strategic resets for signs of a turnaround. If today’s volatility has you rethinking your approach, it might be the perfect time to check out See the full list for free. The stock’s sharp slide and deep discounts to analyst targets raise a key question for investors: is the recent weakness a sign CSL is undervalued and ripe for a rebound, or is the market already factoring in future risks and slowing growth? AdvertisementMost Popular Narrative: 28.5% Undervalued CSL's most watched narrative points to a substantial gap between the analyst fair value and the last close, highlighting optimism despite recent falls. Supporters of this view see notable upside, provided certain catalysts deliver as expected.  CSL is undertaking significant operational transformation initiatives, targeting over $0.5 billion in cost savings by FY28, focusing on increased efficiency in plasma collection, manufacturing, and R&D, which should expand margins and support stronger net earnings growth as these benefits are realized.  Read the complete narrative. Curious how this valuation stacks up? The narrative leans on aggressive improvements in profitability and margin expansion, as well as ambitious growth in new therapies. Unpack the assumptions that could reshape CSL’s price tag. Result: Fair Value of $246.49 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, risks such as ongoing price competition and slower uptake of new products could challenge even the most optimistic forecasts for CSL’s recovery. Find out about the key risks to this CSL narrative.  Build Your Own CSL Narrative If you want to dig into the numbers yourself, or offer a different perspective, you can build your own narrative in just a few minutes, Do it your way A good starting point is our analysis highlighting 6 key rewards investors are optimistic about regarding CSL. Ready for More Investment Ideas? Don’t let your investment journey stop here. Powerful opportunities await. See what you could be missing by checking out more unique stock ideas below.  Supercharge your portfolio by scanning for these 840 undervalued stocks based on cash flows that are primed for strong returns based on their cash flow fundamentals. Capture reliable income and bolster your holdings with these 20 dividend stocks with yields > 3% yielding over 3% annually. Stay ahead of innovation and harness growth by targeting these 26 AI penny stocks pushing boundaries in artificial intelligence.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}